FIGURE 2.

Summary of biological and technological advantages of processing and using FPCs as therapeutic agents, production intermediates, or substrates. From one single fetal organ donation (i.e., FE002, 2009), various tissue samples (e.g., bone, cartilage, intervertebral disc, lung, muscle, skin, tendon) were bioprocessed for FPC isolation using both enzymatic and non-enzymatic methods. Inherent technical and clinical advantages are attributed to FPCs. Various proposed mechanisms of action (MoA) of allogenic FPCs are summarized. Optimized and consistent tissue procurement, cell isolation, and biobanking workflows allow for thorough testing throughout the manufacturing continuum, ensuring quality and safety of end-products.